

Alberto Zanetto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5618688/publications.pdf>

Version: 2024-02-01

78
papers

1,607
citations

279487

23
h-index

360668

35
g-index

80
all docs

80
docs citations

80
times ranked

2009
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. <i>Transplant International</i> , 2018, 31, 1318-1329.	0.8	84
2	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.4	66
3	Current challenges and future directions for liver transplantation. <i>Liver International</i> , 2017, 37, 317-327.	1.9	62
4	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62
5	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo- and Hypercoagulable Features. <i>Hepatology</i> , 2020, 72, 1327-1340.	3.6	60
6	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59
7	Markers of acute rejection and graft acceptance in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 1061.	1.4	57
8	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	1.7	51
9	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	1.3	46
10	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	3.6	45
11	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	1.8	43
12	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.	1.1	42
13	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	1.8	41
14	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	1.9	39
15	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	1.1	37
16	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	1.8	37
17	Liver transplantation for viral hepatitis in 2015. <i>World Journal of Gastroenterology</i> , 2016, 22, 1570.	1.4	36
18	Therapeutic approaches for portal biliopathy: A systematic review. <i>World Journal of Gastroenterology</i> , 2016, 22, 9909.	1.4	35

#	ARTICLE	IF	CITATIONS
19	Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 272-282.	2.0	35
20	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. <i>World Journal of Gastroenterology</i> , 2018, 24, 4403-4411.	1.4	31
21	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016, 143, 118-121.	0.8	29
22	Long-term care of transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 187-195.	0.8	29
23	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	1.9	29
24	Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 46.	1.7	26
25	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. <i>Transplant International</i> , 2014, 27, 877-891.	0.8	23
26	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. <i>Thrombosis Research</i> , 2015, 135, 292-297.	0.8	23
27	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.4	23
28	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2018, 38, 260-269.	1.8	23
29	Influence of donor and recipient gender on liver transplantation outcomes in Europe. <i>Liver International</i> , 2020, 40, 1961-1971.	1.9	22
30	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1168-1176.	1.0	21
31	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	1.7	21
32	Recent advances in understanding and managing liver transplantation. <i>F1000Research</i> , 2016, 5, 2895.	0.8	21
33	The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. <i>Hepatology</i> , 2023, 77, 640-658.	3.6	21
34	Management of acute variceal hemorrhage. <i>F1000Research</i> , 2019, 8, 966.	0.8	20
35	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	1.0	20
36	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3867.	1.0	20

#	ARTICLE	IF	CITATIONS
37	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.4	17
38	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17
39	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	2.6	17
40	Milestones in the discovery of Budd-Chiari syndrome. <i>Liver International</i> , 2019, 39, 1180-1185.	1.9	16
41	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16
42	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	0.6	15
43	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. <i>Platelets</i> , 2015, 26, 577-582.	1.1	14
44	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , 2018, 10, 222-230.	0.8	14
45	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	0.8	12
46	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	1.9	12
47	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , 2021, 10, 3818.	1.0	12
48	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. <i>Liver International</i> , 2018, 38, 1316-1321.	1.9	9
49	Perioperative management of antithrombotic treatment. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2020, 34, 35-50.	1.7	7
50	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	7
51	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis". <i>Platelets</i> , 2022, 33, 1104-1106.	1.1	6
52	Hemodynamic Evaluation of Nonselective β^2 -Blockers in Patients with Cirrhosis and Refractory Ascites. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	5
53	Some Answers and More Questions About Portal Vein Thrombosis in Patients With Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2432-2434.	2.4	5
54	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation " a multicenter cohort study. <i>Transplant International</i> , 2021, 34, 743-753.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Hepatic benefits of HCV cure: Don't forget coagulation!. <i>Journal of Hepatology</i> , 2021, 74, 967-968.	1.8	5
56	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 632-643.	0.5	5
57	Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. <i>World Journal of Hepatology</i> , 2016, 8, 1012.	0.8	5
58	Young GI angle: Challenges and opportunities as a trainee editor: The United European Gastroenterology journal experience. <i>United European Gastroenterology Journal</i> , 2022, 10, 348-353.	1.6	5
59	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.4	5
60	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. <i>Transplant International</i> , 2016, 29, 694-697.	0.8	4
61	An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. <i>American Journal of Medicine</i> , 2022, 135, 157-166.	0.6	4
62	HCC criteria for liver transplantation: Controversies. <i>Liver Transplantation</i> , 2015, 21, S27-S31.	1.3	3
63	Assessment of Bleeding Risk in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2015, 14, 9-18.	0.4	3
64	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	3
65	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 253-259.	0.4	3
66	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, 26-37.	0.3	3
67	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, 4-10.	0.3	3
68	Hepatitis B and liver transplantation. <i>Minerva Gastroenterology</i> , 2018, 64, 147-157.	0.3	2
69	Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. <i>Transplant International</i> , 2017, 30, 239-242.	0.8	1
70	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	0.8	1
71	Reply to "Acute kidney injury in patients with decompensated cirrhosis". <i>Digestive and Liver Disease</i> , 2021, 53, 1217-1218.	0.4	1
72	Gastroesophageal Variceal Bleeding Management. , 2020, , 39-66.		1

#	ARTICLE	IF	CITATIONS
73	Acute alcoholic hepatitis and liver transplantation: Waiting for Godot. Liver International, 2017, 37, 1408-1408.	1.9	1
74	Letter to the editor: Is PAI a thrombotic biomarker in NASH cirrhosis?. Hepatology, 2022, 76, E16-E17.	3.6	1
75	Reply. Liver Transplantation, 2017, 23, 1630-1631.	1.3	0
76	Extending transplantation criteria for hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2017, 2, 546-547.	3.7	0
77	Management of Thrombosis in the Liver Transplant Candidate. , 2019, , 119-146.		0
78	History of Budd-Chiari Syndrome. , 2020, , 1-14.		0